Diabetes mellitus, hyperglycaemia and cancer

Diabetes and Metabolism

Volumn 36, Issue 3, 2010, Pages 182-191

  Simon, D ^a,b,c   Balkau, B ^c  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

Author keywords

Cancer; Epidemiology; Growth factors; Hyperinsulinemia; Review; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIPHASIC INSULIN; GLUCOSE; GROWTH FACTOR; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; INSULIN SENSITIZING AGENT; ISOPHANE INSULIN; METFORMIN; PIOGLITAZONE; SULFONYLUREA;

BREAST CANCER; CANCER RISK; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CANCER; DIABETES MELLITUS; DIETARY INTAKE; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LIFESTYLE; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREAS CANCER; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PROSTATE CANCER; REVIEW; RISK FACTOR; VASCULAR DISEASE; FEMALE; HYPERINSULINISM; MALE; METABOLISM;

DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERGLYCEMIA; HYPERINSULINISM; MALE; NEOPLASMS; RISK FACTORS;

EID: 77953480614     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2010.04.001     Document Type: Review

References (64)

1. Fuller J.H., Elford J., Goldblatt P., and Adelstein A.M. Diabetes mortality: new light on an underestimated public health problem. Diabetologia 24 (1983) 336-341
2. Green A., and Hougaard P. Epidemiological studies of diabetes mellitus in Denmark. 5. Mortality and causes of death among insulin-treated diabetic patients. Diabetologia 20 (1984) 468-470
3. Steenland K., Nowlin S., and Palu S. Cancer incidence in the National Health and Nutrition Survey I. Follow-up data: diabetes, cholesterol, pulse, and physical activity. Cancer Epidemiol Biomarkers Prevention 4 (1995) 807-811
4. Shoff S.M., and Newcomb P.A. Diabetes, body size, and risk of endometrial cancer. Am J Epidemiol 148 (1998) 234-240
5. Calle E.E., Rodriguez C., Walker-Thurmond K., and Thun M.J. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 348 (2003) 1625-1638
6. Huxley R., Ansary-Moghaddam A., Berrington de Gonzalez A., Barzi F., and Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92 (2005) 2076-2083
7. Hemkens L.G., Grouven U., Bender R., Günster C., Gutschmidt S., Selke G.W., et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52 (2009) 1732-1744
8. Jonasson J.M., Ljung R., Talbäck M., Haglund B., Gudbjörnsdöttir S., and Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 52 (2009) 1745-1754
9. Colhoun H.M., and SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52 (2009) 1755-1765
10. Currie C.J., Poole C.D., and Gale E.A.M. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52 (2009) 1766-1777
11. Green A., and Jensen O.M. Frequency of cancer among insulin-treated diabetic patients in Denmark. Diabetologia 28 (1985) 128-130
12. Zendehdel K., Nyrén O., Östenson C.G., Adami H.O., Ekbom A., and Ye W. Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Nat Cancer Inst 23 (2003) 1797-1800
13. Inoue M., Iwasaki M., Otani T., Sasazuki S., Noda M., Tsugane S., and for the Japan Public Health Center-based Prospective Study Group. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Int Med 166 (2006) 1871-1877
14. Tseng C.H., Chong C.K., and Tai T.Y. Secular trend for mortality from breast cancer and the association between diabetes and breast cancer in Taiwan between 1995 and 2006. Diabetologia 52 (2009) 240-246
15. Larsson S.C., Mantzoros C.S., and Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 121 (2007) 856-862
16. Stattin P., Björ O., Ferrari P., Lukanova A., Lenner P., Lindahl B.G., et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care 30 (2007) 561-567
17. Jee S.H., Ohrr H., Sull J.W., Yun J.E., Ji M., and Samet J.M. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 293 (2005) 194-202
18. Rapp K., Schroeder J., Klenk J., Ulmer H., Concin H., Diem G., et al. Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia 49 (2006) 945-952
19. Bonovas S., Filioussi K., and Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia 47 (2004) 1071-1078
20. Kasper J.S., and Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15 (2006) 2056-2062
21. Khaw K.T., Wareham N., Bingham S., Luben R., Welch A., and Day N. Preliminary communication: glycated haemoglobin, diabetes, and incident colorectal cancer in men and women: a prospective analysis from the European Prospective Investigation into Cancer-Norfolk Study. Cancer Epidemiol Biomarkers Prev 13 (2004) 915-919
22. Doll R. The lessons of life: keynote address to the nutrition and cancer conference. Cancer Res 52 7 Suppl. (1992) 2024S-2029S
23. International Agency for Research on Cancer: IARC handbooks of cancer prevention. Vol.8: Fruit and vegetables. Lyon, France 2003.
24. Pan X.R., Li G.W., Hu Y.H., Wang J.X., Yang W.Y., An Z.X., et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and diabetes study. Diabetes Care 20 (1997) 537-544
25. Tuomilehto J., Lindström J., Eriksson J.G., Valle T.T., Hamalainen H., Ilanne-Parikka P., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344 (2001) 1343-1350
26. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
27. Friedenreich C.M. Physical activity and cancer prevention: from observational to intervention research. Cancer Epidemiol Biomarkers Prev 10 (2001) 287-301
28. Khandwala H.M., McCutcheon I.E., Flyvberg A., and Friend K.E. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21 (2000) 215-244
29. Wolf I., Sadetzki S., Catane R., Karasik A., and Kaufman B. Diabetes mellitus and breast cancer. Lancet Oncol 6 (2005) 103-111
30. Le Roith D. Seminars in medicine on the Beth Israel Deaconess Medical Center: insulin-like growth factors. N Engl J Med 336 (1997) 633-640
31. Balkau B., Kahn H.S., Courbon D., Eschwège E., and Ducimetière P. Hyperinsulinemia predicts fatal liver cancer but is inversely associated with fatal cancer at some other sites. The Paris Prospective Study. Diabetes Care 24 (2001) 843-849
32. Maison P., Balkau B., Simon D., Chanson P., Rosselin G., and Eschwège E. Growth hormone, a risk factor for premature mortality in healthy subjects. Data from the Paris Prospective Study. BMJ 316 (1998) 1132-1133
33. Major J.M., Laughlin G.A., Kritz-Silverstein D., Wingard D.L., and Barrett-Connor E. Insulin-like growth factor-1 and cancer mortality in older men. J Clin Endocrinol Metab 95 (2010) 1054-1059
34. Goodman-Gruen D., and Barrett-Connor E. Sex differences in the association of endogenous sex hormone levels and glucose tolerance status in older men and women. Diabetes Care 23 (2000) 912-918
35. Gann P.H., Hennekens C.H., Ma J., Longcope C., and Stampfer M.J. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 88 (1996) 1118-1126
36. Frayling T.M., Colhoun H., and Florez J.C. A genetic link between type 2 diabetes and prostate cancer. Diabetologia 51 (2008) 1757-1760
37. Bowker S.L., Majumdar S.R., Veugelers P., and Johnson J.A. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29 (2006) 254-258
38. Hawley S.A., Boudeau J., Reid J.L., Mustard K.J., Udd L., Makela T.P., et al. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2 (2003) 28
39. Lizcano J.M., Göransson O., Toth R., Deak M., Morrice N.A., Boudeau J., et al. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J 23 (2004) 833-843
40. Evans J.M.M., Donnelly L.A., Emslie-Smith A.M., Alessi D.R., and Morris A.D. Metformine and reduced risk of cancer in diabetic patients. Br Med J 330 (2005) 1304-1305
41. Libby G., Donnelly L.A., Donnan P.T., Alessi D.R., Morris A.D., and Evans J.M.M. New users of metformine are at low risk of incident cancer. Diabetes Care 32 (2009) 1620-1625
42. Landman G.W.D., Kleefstra N., Van Hateren K.J.J., Groenier K.H., Gans R.O.B., and Bilo H.J.G. Metformin associated with lower cancer mortality in type 2 diabetes. Diabetes Care 33 (2010) 322-326
43. Yang Y.X., Hennesy S., and Lewis J.D. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 127 (2004) 1044-1050
44. Dormandy J., Charbonnel B., Eckland D.J.A., Erdmann E., Massi-Benedetti M., Skene A.M., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
45. Govindarajan R., Ratnasinghe L., Simmons D.L., Siegel E.R., Midathada MVKim L., et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 12 (2007) 1476-1481
46. Monami M., Lamanna C., Marchionni N., and Mannucci E. Rosiglitazone and risk of cancer. A meta-analysis of randomized clinical trials. Diabetes Care 31 (2008) 1455-1460
47. Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., et al. Glycemic durability of rosiglitazone, metformine or glyburide monotherapy. N Engl J Med 355 (2006) 2427-2443
48. Murtola T.J., Tammela L.J., Lahtela J., and Auvinen A. Antidiabetic medication and prostate cancer risk: a population-based case-control study. Am J Epidemiol 168 (2008) 925-931
49. Simon D., Preziosi P., Barrett-Connor E., Roger M., Saint-Paul M., Nahoul K., et al. The influence of aging on plasma sex hormones in men: the Telecom Study. Am J Epidemiol 135 (1992) 783-791
50. Kurtzhals P., Schäffer L., Sørensen A., Kristensen C., Jonassen I., Schmid C., et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49 (2000) 999-1005
51. Pocock S.J., and Smeeth L. Insulin glargin and malignancy: an unwarranted alarm. Lancet 374 (2009) 511-513
52. Garg S.K., Hirsch I.B., and Skyler J.S. Insulin glargine and cancer-An ubsubstantiated allegation. Diabetes Techn Ther 11 (2009) 473-476
53. Nagel J.M., Mansmann U., Wegscheider K., and Röhmel J. Insulin resistance and increased risk for malignant neoplasms: confounding the data on insulin glargine. Diabetologia 53 (2010) 206-208
54. Simon D. Diabetes treatment with insulin glargine and risk of malignancy: methodological pitfalls and ethical issues. Diabetologia 53 (2010) 204-205
55. Grouven U., Hemkens L.G., Bender R., and Sawicki P.T. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues. Diabetologia 53 (2010) 209-211 [Reply to Nagel JM, Mansmann U, Wegscheider K et al. (letter) and Simon D (letter)]
56. Yki-Järvinen H., Kauppinen-Mäkelin R., Tikkainen M., Vähätalo M., Virtamo H., Nikkilä K., et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 49 (2006) 442-451
57. Pan C.Y., Sinnassamy P., Chung K.D., Kim K.W., and On behalf of the LEAD Study Investigators Group. Insulin glargine vs NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Res Clin Pract 76 (2007) 111-118
58. Riddle M.C., Rosenstock J., Gerich J., and on behalf of the Insuline Glargine 4002 Study Investigators. The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 (2003) 3080-3086
59. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
60. Bender R., and Lange S. Adjusting for multiple testing-when and how?. J Clin Epidemiol 54 (2001) 343-349
61. Smith U., and Gale E.A.M. Does diabetes therapy influence the risk of cancer?. Diabetologia 52 (2009) 1699-1708
62. Romon I., Jougla E., Weill A., Eschwège E., Simon D., and Fagot-Campagna A. Description de la mortalité et des causes de décès dans une cohorte d'adultes diabétiques, en France métropolitaine-ENTRED 2001. Bull Epidemiol Hebd 42-43 (2009) 469-472
63. Eyre H., Kahn R., Robertson R.M., and On behalf of the ACS/ADA/AHA Collaborative writing Committee. Preventing cancer, cardiovascular disease, and diabetes-A common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. Diabetes Care 27 (2004) 1812-1824
64. Hercberg S., Chat-Yung S., and Chaulia M. The French National Nutrition and Health Program: 2001-2006-2010. Int J Public Health 53 (2008) 68-77